Comparing real-life carbamazepine exposure between innovator and generic formulation - 27/09/22
, Sarah Zerei a, Rim Charfi a, b, c, Issam Salouage a, b, c, Mouna Ben Sassi a, b, c, Hanene El Jebari a, b, Riadh Daghfous a, b, c, Sameh Trabelsi a, b, cSummary |
Background |
Carbamazepine is an anticonvulsant largely used in the treatment of epilepsy. The use of generic antiepileptic drugs (AEDs) is controversial because of the eventual possibility to loss seizures control. The aim of our study was to compare the concentration over dose ratio of two products containing carbamazepine, the innovator (Tégrétol®-NOVARTIS) and the generic (Taver®-MEDOCHEMIE).
Methods |
It is a retrospective study (2009-2016) including 32 patients treated with carbamazepine. Patients were treated initially by innovator then switched to generic or vice versa. All patients have at least one level of carbamazepine plasma concentration (C0) with the innovator or the generic formulation. Monitoring of carabamazepine was made using immunoassay method (ARCHITECT-ABOTT®).
Results |
The mean age of our patients was 28.4 years and ranged from 2 to 55 years. The sex ratio M/F was 1.46. The mean ratio C0/dose for the innovator group was 0.723 (min/max: 0.017/1.73), and the mean ratio C0/dose for the generic group was also 0.607 (min/max: 0.064/1.68). There was no statistically significant difference between both groups (P=0.16).
Conclusion |
Our results confirm the difference between the innovator and the generic formulation of carbamazepine. So, switching from innovator to generic seems to be safe and exposure to carbamazepine remains the same.
Le texte complet de cet article est disponible en PDF.Keywords : Antiepileptic, Generic, Bioavailability
Plan
Vol 77 - N° 5
P. 523-526 - septembre 2022 Retour au numéro
Article précédent
- Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)
- Florian Lemaitre, Matthieu Grégoire, Caroline Monchaud, Stéphane Bouchet, Béatrice Saint-Salvi, Elisabeth Polard, SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT), French Pharmacovigilance Network (CRPV), ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group, The SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT), French Pharmacovigilance Network (CRPV), ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group, Sihem Benaboud, Laurent Chouchana, Jean-Luc Cracowski, Milou-Daniel Drici, Rodolphe Garraffo, Romain Guilhaumou, Annie-Pierre Jonville-Bera, Mathieu Molimard, Patric Muret, Gilles Peytavin, Vincent Richard, Caroline Solas
- Trigger tools to identify adverse drug events in hospitalised children: A systematic review
- Rama Arab, Catherine Cornu, Roubi Kilo, Aurélie Portefaix, Beatriz Fretes-Bonett, Fanny Hergibo, Behrouz Kassai, Kim An Nguyen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?